AstraZeneca completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer September 9, 2026
Styx Biotechnologies Announces Strategic Agreement with ZoeNCure Therapeutics to Accelerate Next-Gen ADC Pipeline to Clinic September 9, 2026
INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Ph 2 HNSCC Study September 9, 2026
Treeline Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate TLN-121 with CD20xCD3 T-Cell-Engaging Bispecific Antibodies September 9, 2026
Positive Topline Results Announced from Ph 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and PFS in RRMM Patients September 9, 2026
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy September 9, 2026
Imfinzi + Imdelltra demonstrated statistically significant OS & PFS improvement in 1L ES-SCLC September 9, 2026
AIM ImmunoTech Secures Broad US Patent for Rintatolimod (Ampligen®) Used in Combination with Keytruda, Expanding Oncology IP Protection for Ampligen Through 2039 September 9, 2026
Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development September 9, 2026
Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line September 9, 2026
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors September 9, 2026
China’s Simnova Bags USD59.5 Million in New Funding to Advance Off-the-Shelf Cell Therapies September 9, 2026
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors September 9, 2026
Typewriter Therapeutics Emerges from Stealth with $56 Million Series A Financing to pursue in vivo CAR T medicines September 9, 2026
Positive Topline Results Announced from Registrational Ph 2 QUINTESSENTIAL Trial of GPRC5D-Directed CAR T Cell Therapy Arlocabtagene Autoleucel September 9, 2026
Positive Outcome Announced from First Planned Interim Efficacy Analysis from FORTE Basket Study of Plixorafenib Monotherapy in Advanced Solid Tumors with BRAF Fusions September 9, 2026
100% Three-Year DFS announced with TG4050 and Ph 1 Results Published in Nature Communications September 9, 2026
NEJM Publishes Ph 1/2 Clinical Data on RASONQUE™ (daraxonrasib) in Metastatic NSCLC September 9, 2026
Ivonescimab Meets OS Key Secondary Endpoint in Interim Analysis of Ph 3 HARMONi-2 Study, Demonstrating Statistically Significant Benefit Versus Pembrolizumab in 1L PD-L1-Positive NSCLC September 9, 2026
Etcamah + CDK4/6 inhibitor combo approved in the US for 1L advanced HR-positive breast cancer September 9, 2026
